Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06254690
Status:
RECRUITING
Last Update Posted:
2024-02-12
First Post:
2024-01-28
Brief Title:
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer a Phase II Clinical Study
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University